Abstract
Acute motor and sensory axonal neuropathy (AMSAN) is a recently described subtype
of Guillain-Barré syndrome characterized by acute onset of distal weakness, loss of
deep tendon reflexes and sensory symptoms. Electrophysiological studies show mildly
reduced nerve conduction velocities combined with a marked reduction of muscle action
and sensory nerve action potentials. Here, we report a 15-year-old boy who suffered
from severe burning and knife-like pain that increased over a period of three months
and resulted in a disrupted sleep pattern and suicidal intentions as well as marked
loss of weight. In addition, he developed muscle weakness in his hands and feet. Neurophysiological
and histopathological studies revealed AMSAN. Marked improvement of his condition
was achieved by treatment with intravenous immunoglobulins, high-dose methylprednisolone,
and a combination of gabapentin, antidepressants, and an oral morphine.
Key words
AMSAN - children - IVIG - pain management
References
- 1
Alam T A, Chaudhry V, Cornblath D R.
Electrophysiological studies in the Guillain-Barré syndrome: Distinguishing subtypes
by published criteria.
Muscle Nerve.
1998;
21
1275-1279
- 2
Backonja M, Beydoun A, Edwards K R, Schwartz S L, Fonseca V, Hes M. et al .
Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes
mellitus: a randomized controlled trial.
JAMA.
1998;
280
1831-1836
- 3
Chowdhury D, Arora A.
Axonal Guillain-Barré syndrome: a critical review.
Acta Neurol Scand.
2001;
103
267-277
- 4
Griffin J W, Li C Y, Ho T W, Tian M, Gao C Y, Xue P. et al .
Pathology of motor-sensory axonal Guillain-Barré syndrome.
Ann Neurol.
1996;
39
17-28
- 5
Hahn K, Arendt G, Braun J S, von Giesen H J, Husstedt I W, Maschke M. et al .
A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies.
J Neurol.
2004;
251
1260-1266
- 6
Ho T W, Hsieh S T, Nachamkin I, Willison H J, Sheikh K, Kiehlbauch J. et al .
Motor nerve terminal degeneration provides a potential mechanism for rapid recovery
in acute motor axonal neuropathy after Campylobacter infection.
Neurology.
1997;
48
717-724
- 7
Khatri A, Pearlstein L.
Pain in Guillain-Barré syndrome.
Neurology.
1997;
49
1474
- 8
Korinthenberg R, Monting J S.
Natural history and treatment effects in Guillain-Barré syndrome: a multicentre study.
Arch Dis Child.
1996;
74
281-287
- 9
Massaro M E, Rodriguez E C, Pociecha J, Arroyo H A, Sacolitti M, Taratuto A L. et
al .
Nerve biopsy in children with severe Guillain-Barré syndrome and inexcitable motor
nerves.
Neurology.
1998;
51
394-398
- 10
Mendell J R, Sahenk Z.
Painful sensory neuropathy.
N Engl J Med.
2003;
348
1243-1255
- 11
Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group .
Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments
in Guillain-Barré syndrome.
Lancet.
1997;
349
225-230
- 12
Sindrup S H, Gram L F, Brosen K, Eshoj O, Mogensen E F.
The selective serotonin reuptake inhibitor paroxetine is effective in the treatment
of diabetic neuropathy symptoms.
Pain.
1990;
42
135-144
- 13
Sindrup S H, Jensen T S.
Pharmacologic treatment of pain in polyneuropathy.
Neurology.
2000;
55
915-920
- 14 Sladky J T.
Guillain-Barré syndrome. Jones HR, de Vivo DC, Darras BT Neuromuscular Disorders of Infancy, Childhood, and
Adolescents. Philadelphia; Butterworth, Heinemann 2003: 407-424
- 15
Yuki N, Kuwabara S, Koga M, Hirata K.
Acute motor axonal neuropathy and acute motor-sensory axonal neuropathy share a common
immunological profile.
J Neurol Sci.
1999;
168
121-126
Kevin Rostásy
Department of Pediatrics and Pediatric Neurology
Georg-August University Göttingen
Robert-Koch-Straße 40
37075 Göttingen
Germany
Email: Krostasy@excite.com
